Page 38 - 2020_02-Haematologica-web

C. Camaschella et al.
for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001-1010.
135. Xavier-Ferrucio J, Scanlon V, Li X et al. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice. Blood. 2019;134(18): 1547-1557.
136. Bordini J, Galvan S, Ponzoni M, et al. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia. 2017;31(4):967-970.
137. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest. 2013;123(4):1531-1541.
138. Garcia-Santos D, Hamdi A, Saxova Z, et al. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-tha- lassemia mouse model. Blood. 2018;131 (2):236-246.
139. Sheetz M, Barrington P, Callies S, et al. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019;85(5):935-948.
140.Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and amelio- rates anemia of chronic disease in rodents. Blood. 2017;129(13):1823-1830.
141. Kovac S, Boser P, Cui Y, et al. Anti-hemoju- velin antibody corrects anemia caused by inappropriately high hepcidin levels.
Haematologica. 2016;101(5):e173-176.
142. Poli M, Asperti M, Naggi A, et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo.
Blood. 2014;123(10):1564-1573. 143.Vadhan-Raj S, Abonour R, Goldman JW, et
al. A first-in-human phase 1 study of a hep- cidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017;10(1):73.
144.Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacody- namics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016;173(10):1580-1588.
145. Hohlbaum AM, Gille H, Trentmann S, et al. Sustained plasma hepcidin suppression and iron elevation by anticalin-derived hepcidin antagonist in cynomolgus monkey. Br J Pharmacol. 2018;175(7):1054-1065.
146.Angmo S, Tripathi N, Abbat S, et al. Identification of guanosine 5'-diphosphate as potential iron mobilizer: preventing the hepcidin-ferroportin interaction and modu- lating the interleukin-6/Stat-3 pathway. Sci Rep. 2017;7:40097.
147. Silvestri L, Nai A, Dulja A, Pagani A. Hepcidin and the BMP-SMAD pathway: an unexpect- ed liaison. Vitam Horm. 2019;110: 71-99.
148. Latour C, Besson-Fournier C, Meynard D, et al. Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morpho-
genetic protein 6 or hemojuvelin.
Hepatology. 2016;63(1):126-137.
149. Zhao N, Nizzi CP, Andrerson SA, et al. Low intracellular iron increases the stability of matriptase-2. J Biol Chem. 2015;290(7):
4432-4446.
150. Schmidt PJ, Toran PT, Giannetti AM,
Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regula- tion of hepcidin expression. Cell Metab. 2008;7(3):205-214.
151.Pasricha SR, Lim PJ, Duarte TL, et al. Hepcidin is regulated by promoter-associat- ed histone acetylation and HDAC3. Nat Commun. 2017;8(1):403.
152. Artuso I, Pettinato M, Nai A, et al. Transient decrease of serum iron after acute erythro- poietin treatment contributes to hepcidin inhibition by ERFE in mice. Haematologica. 2019;104(3):e87-e90.
153.Xiao X, Dev S, Canali S, et al. Endothelial Bmp2 knockout exacerbates hemochro- matosis in Hfe knockout mice but not Bmp6 knockout mice. Hepatology. 2019 Nov 28. [Epub ahead of print]
154. Wang CY, Xu Y, Traeger L, et al. Erythroferrone lowers hepcidin by seques- tering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood. 2019 Dec 4. [Epub ahead of print]
155. Manolova V, Nyffenegger N, Flace A, et al. Oral ferroportin inhibitor ameliorates inef- fective erythropoiesis in a model of β-tha- lassemia. J Clin Invest. 2019;130(1):491-506
272
haematologica | 2020; 105(2)